Henry Schein opened higher at $86.57, compared with its previous close of $86.44. In the last trading session, the stock traded between $84.69 and $86.95. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Henry Schein is now worth
$ 111.52
giving a profit of
$ 11.52 (11.52%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 16 Analysts
Buy
56.25%
Hold
37.5%
Sell
6.25%
Markets Today
Today's Change
$-1.29 (-1.50%)
Day High
$86.95
Day Low
$84.69
Day Open
$86.57
Prev Close
$86.44
Volume
4,11,986
1W Return
-1.02%
1M Return
0.19%
3M Return
-0.81%
6M Return
15.37%
1Y Return
36.63%
Fundamentals
Market Cap ($ Mn)
9,489
PE Ratio
26.10
PB Ratio
3.17
PEG Ratio
16.49
ROE
12.50%
ROCE
8.37%
EPS (TTM)
$0.84
Investment Returns
1 Week
-1.02%
1 Month
0.19%
3 Months
-0.81%
6 Months
15.37%
9 Months
14.54%
Financials
Quarterly
All values in $ Mn
3.2K
Mar 25
3.2K
Jun 25
3.3K
Sep 25
3.4K
Dec 25
3.4K
Mar 26
3.5K
Jun 26
Updates
15Oct
Leerink Partners lowers Henry Schein price target to $92, keeps Market Perform
Leerink Partners lowered Henry Schein's price target from $96 to $92. Analyst Michael Cherny maintained a Market Perform rating. The revision reduces the previous target by $4.
15 days ago
25Sep
Henry Schein Q2FY26 Results: Non-GAAP EPS up 15.5%, guidance raised
Non-GAAP EPS rose 15.5% to $1.27, outpacing 6.7% sales growth. Full-year FY26 sales guidance raised to 4.5%-5.5%, EPS to $5.29-$5.39. U.S. dental merchandise sales grew 8.3%, international dental merchandise up 11.1%. High-margin businesses now contribute nearly 50% of total operating income.
1mo ago
6Aug
UBS raises Henry Schein price target to $94 on neutral outlook
UBS analyst Kevin Caliendo maintains a Neutral rating on Henry Schein Inc. (NASDAQ: HSIC) but raises the price target from $89 to $94. This adjustment reflects a refined valuation assessment rather than a shift in investment strategy. The higher target suggests improved fair value estimates, though the Neutral stance indicates the stock is currently seen as fairly priced with limited immediate upside.
2mo ago
4Aug
Henry Schein Q2 Results: Sales rise 6.7%, EPS up 15.5%
Henry Schein delivered strong Q2 2026 results with $3.5 billion in sales, up 6.7% YoY, and non-GAAP EPS of $1.27, a 15.5% increase. Driven by margin expansion and market share gains in dental merchandise, the company raised full-year guidance for sales growth to 4.5%-5.5% and EPS growth to 6%-8%. Strategic focus on AI-enabled technology and value creation initiatives supports long-term profitability.
2mo ago
21Jul
Henry Schein to announce Q2 2026 results on August 4
Henry Schein will release its Q2 2026 financial results before the market opens on August 4, 2026, followed by a live webcast at 8:00 a.m. ET. CEO Fred Lowery and CFO Ronald N. South will host the call, accessible via the company's investor relations website.
3mo ago
9Jul
BMO Capital initiates coverage on Henry Schein with $85 price target
BMO Capital initiates coverage on Henry Schein with a Market Perform rating and a price target of $85.
